Previous studies have shown that TRIP13 plays an oncogene role in various tumours and is involved in tumour cell proliferation, apoptosis, migration, and invasion, including colorectal cancer, head and neck cancer, glioblastoma, cervical cancer, multiple myeloma, hepatocellular carcinoma, and cholangiocarcinoma [8, 12–17]. This evidence concerns the gene TRIP13 and plasma cell myeloma.